Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

[powerpress]

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

[powerpress]